Document:

EX-4.33

 Exhibit 4.33 
 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the Securities and Exchange Commission. 

EUV NRE FUNDING AGREEMENT 
 This EUV NRE Funding Agreement (the “Agreement”) is (i) made on July 9, 2012 by and between ASML Holding N.V. (“ASML”), a Dutch corporation, and Intel
Corporation (“Funding Partner”), a Delaware corporation (each, a “Party,” and collectively, the “Parties”) and (ii) effective upon the Additional Closing (as defined in that certain Investment
Agreement between Intel Corporation and ASML Holding N.V. dated as of the date hereof) or such earlier date as the Parties may agree or be advised by counsel that such effectiveness is not subject to any approval, consent, clearance or waiver under
applicable law that has not been obtained (“Effective Date”). 
 WHEREAS 

 

	 	•	 	 ASML is engaged in research and development activities to develop and advance the technologies described in the road map attached hereto as Appendix 1
(such Appendix, the “Roadmap” and such research and development activities, the “Project”); 

  

	 	•	 	 ASML is selling and issuing to Funding Partner, and Funding Partner is purchasing from ASML, an interest in ordinary shares of ASML, pursuant to that
certain Investment Agreement, by and between ASML Holding N.V. and Funding Partner (the “Investment Agreement”); 

  

	 	•	 	 Subject to the Additional Closing of the Investment Agreement (as defined therein) Funding Partner desires that ASML invests sufficiently in the
Project, and desires to assist ASML with the Project by funding certain of ASML’s expenses with respect to the Project. 

  

	 	•	 	 For avoidance of doubt, Funding Partner’s intent in entering this Agreement is to reduce the risk of execution of and to enable the Project and
ensure that the Project related lithography systems are available to Funding Partner and the whole industry, without limitation or encumbrances. 

 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and
intending to be legally bound, it is therefore agreed as follows: 
  

	1	Project Assignment. 

  

	 	1.1	Funding Partner agrees to fund a portion of ASML’s research and development expenses, dedicated capital expenditures, non-recurring engineering costs, and
third party costs (collectively, “Project Expenditures”) targeted at developing the Project described in the Roadmap. ASML’s good faith estimate, as of the Effective Date, of the total Project Expenditures during the period
starting on January 1, 2013 and ending on December 31, 2017 (the “Funding Period”) is attached hereto as Appendix 2 (such Appendix, the “Project Expenditure Estimate”). 

  
 1 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	1.2	During the Funding Period, ASML will in good faith use its commercially reasonable efforts to execute the Project in a manner that will lead to the achievement
of the Roadmap under the most recent Project Expenditure Estimate. Funding Partner acknowledges and agrees that (a) ASML shall have sole control of the Project, (b) ASML is not committing to or guaranteeing the results of the Project or
the suitability of the technologies described in the Roadmap for Funding Partner’s purposes. 

  

	 	1.3	ASML may change the Project Expenditure Estimate at any time, in its sole discretion. ASML will provide Funding Partner with an updated Project Expenditure
Estimate, based on ASML’s then-current good faith evaluation of the state of the Project (a) within thirty (30) days prior to the start of each calendar year during the Funding Period and (b) promptly after ASML makes a
significant change to the then-current Project Expenditure Estimate. 

  

	2	Project Funding. 

  

	 	2.1	During the Funding Period, Funding Partner will pay to ASML a total of €276,000,000 (the “Partner Funding”). Unless otherwise agreed in
writing by the Parties, ASML shall apply the Partner Funding to the Project. 

  

	 	2.2	Within thirty (30) days prior to the start of each calendar year during the Funding Period, ASML will provide Funding Partner with (a) a statement of
the portion of the Partner Funding that Funding Partner will pay to ASML at the start of each calendar quarter of the next calendar year (each, a “Quarterly Payment”) and (b) a high-level report specifying in reasonable detail
the actual Project Expenditures during the current calendar year; provided, that ASML shall not be required to provide such a report for calendar year 2012. 

 

	 	2.3	Subject to Section 2.4, the amount of each Quarterly Payment will be calculated by (a) dividing the then-remaining Partner Funding (i.e., the
initial Partner Funding minus all prior Quarterly Payments actually made by Funding Partner) by ASML’s most recent Project Expenditure Estimate for the remainder of the Funding Period and (b) multiplying the result by the amount set forth
in the most recent Project Expenditure Estimate with respect to each calendar quarter during the remainder of the Funding Period. 

  

	 	2.4	 Funding Partner acknowledges and agrees that ASML’s actual Project Expenditures for a given calendar year may be less than the last Project
Expenditure Estimate issued prior to such calendar year, and that such situation shall not have any consequences, as the total Funding for the Funding Period will remain unchanged. Notwithstanding the foregoing, if ASML’s actual Project
Expenditures for any calendar year (other than the last calendar year of the Funding Period) are *** percent (***%) or more lower than the last Project Expenditure Estimate issued prior to such calendar year, then Funding Partner may request a
reimbursement of the extra funding paid by Funding partner above 

  
 2 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
what should have been paid on actual costs; the total overall committed funding should however still be paid during the funding period. 

If (a) ASML, in its reasonable discretion, decides to abandon the Project as a result of technical infeasibility or lack of
sufficient industry demand required to sustain ASML’s production capacity and supply chain readiness at *** (***) tools per month and cease research and development activities with respect to the technologies described in the Roadmap or
(b) if the then-remaining Partner Funding (i.e., the initial Partner Funding minus all prior Quarterly Payments actually made by Funding Partner) is more than *** percent (***%) of such updated Project Expenditure Estimate for the
remainder of the Funding Period, then ASML and Funding Partner will in good faith seek to agree to apply the remaining Partner Funding to a different, mutually agreed ASML development project. If the Parties so agree on a replacement project, such
replacement project shall be considered the “Project” for all purposes under this Agreement. If the Parties cannot agree on a replacement project, then ASML may invoice Funding Partner per latest funding forecast at the end of each
calendar year the remaining due portion during each year of the remaining Funding Period in which ASML’s actual gross research and development expenditures exceed €*** before funding; ASML will further invoice Funding Partner for the
balance due on the originally committed funding, if any, in the year following the end of the funding period. 
  

	3	Term and Termination. 

  

	 	3.1	The term of this Agreement (the “Term”) shall commence on the Effective Date and continue in full force and effect until December 31, 2017,
unless earlier terminated in accordance with the terms of this Agreement. 

  

	 	3.2	Funding Partner may terminate this Agreement upon thirty (30) days’ written notice to ASML and by paying to ASML a lump sum amount equal to the
remaining Partner Funding (i.e., the initial Partner Funding minus all prior Quarterly Payments actually made by Funding Partner) as of the date of such termination. The Parties acknowledge and agree that this Section 8.2 sets forth the
sole and exclusive right to terminate this Agreement, and that there are no other termination rights, express or implied, under this Agreement. 

  

	 	3.3	In the event of any expiration or termination of this Agreement, each Party shall promptly return to the other Party all Confidential Information and copies
thereof belonging to the other Party which are related to the Agreement and are then in the possession, power, or control of such Party or any of its personnel; provided, that such Party shall nevertheless be entitled to retain copies of any
of the foregoing (and related documentation) in accordance with its general records retention policy and to satisfy its obligations under applicable law or regulation. 

 

	 	3.4	 Expiration or termination of this Agreement for any reason shall not affect any liabilities or obligations of either Party arising before such
expiration or termination or out of the events causing such termination, or any damages or other 

  
 3 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
remedies to which a Party may be entitled under this Agreement, at law or in equity, arising from any breaches of such liabilities or obligations. 

 

	 	3.5	Sections 6,7,8,9, and 10 and any other rights or obligations which by their nature and content are expressly or impliedly intended to survive, shall survive and
continue following expiration or termination of this Agreement. 

  

	4	Payment Terms. 

  

	 	4.1	Funding Partner shall pay each Quarterly Payment to ASML on the first day of the applicable calendar quarter. 

 

	5	Audit. 

  

	 	5.1	ASML shall maintain records in sufficient detail to permit Funding Partner to confirm the actual Project Expenditures for each calendar quarter during the
Funding Period. Upon written notice to ASML, Funding Partner shall have the right, no more than one (1) time per calendar year and at its own expense, using an independent auditor selected by Funding Partner and reasonably acceptable to ASML,
to review such records (to the extent generated since the last audit conducted by Funding Partner pursuant to this Section 5.1) during normal business hours, solely to verify the applicable actual Project Expenditures. ASML shall reasonably
cooperate with such audit, and Funding Partner shall provide ASML with a copy of all reports and other findings prepared in connection with such audit. 

  

	 	5.2	If Funding Partner’s exercise of its rights under Section 5.1 results in audit findings that the actual Project Expenditures reported by ASML for a given
calendar year are less than *** percent (***%) of the last Project Expenditure Estimate prior to the start of such calendar year, then the Parties will meet to discuss such findings and, if the findings are confirmed by ASML, ASML will reimburse the
extra funding paid by Funding partner above what should have been paid on actual costs and will restate accordingly the Funding due for the remainder of the Funding Period, which will in any event ensure that the total funding committed will be
paid. 

  

	6	Confidentiality. 

  

	 	6.1	 During the Term of the Agreement, either Party may have or may be provided access to the other Party’s confidential information and
material. For purposes of this Agreement, “Confidential Information” means all non-public and/or proprietary information of one of the Parties (the “Disclosing Party that is disclosed to the other Party (the
“Receiving Party”) in the course of the activity pursuant to this Agreement, whether disclosed in oral, written, graphic, machine recognizable (including computer programs or data bases), model or sample form, or any derivation
thereof, and includes product specifications, designs, production plans, bills of materials, development schedules, processes, method. Such information shall be Confidential Information if it would ordinarily be treated as

  
 4 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
confidential by the Disclosing Party or would ordinarily be considered information of a confidential nature in the industry, whether or not specifically marked as such. The Receiving Party shall
hold the Disclosing Party’s Confidential Information in strictest confidence, using such measures as the Receiving Party uses to protect the confidentiality of its own Confidential Information of like importance, but in no event using less than
reasonable care. 

  

	 	6.2	The Receiving Party shall not make any disclosure of such Confidential Information other than to its employees or agents on a need to know basis. The Receiving
Party shall inform each such employee or agent of the Receiving Party’s confidentiality obligations under this Agreement, and shall be jointly and severally liable for any breach of this Agreement by any such employee. 

 

	 	6.3	The provisions of this Article 6 shall not apply to any information that is: (a) in or subsequently enters the public domain, other than by fault, act or
omission of the Receiving Party, (b) obtained lawfully from a third person who was under no obligation of confidentiality, (c) independently developed by the Receiving Party without reference to any Confidential Material, or
(d) required to be disclosed by law or regulation or in response to a valid court order; provided, however, that the Receiving Party shall, if legally permitted, give the Disclosing Party prior notice as soon as possible of such
required disclosure so as to enable the Disclosing Party to seek relief from such disclosure requirement or undertake measures to protect the confidentiality of the disclosure. 

 

	 	6.4	Any and all written reports prepared by and any information provided by ASML in connection herewith shall be maintained in strict confidence and may not be
disclosed, in whole or in part, by Funding Partner to any third party without the prior written consent of ASML. 

  

	 	6.5	The Receiving Party shall immediately inform the Disclosing Party if it becomes aware of the possession, use, or knowledge of any of the Confidential Information
by any person not authorized to possess, use, or have knowledge of the Confidential Information and shall, at the request of the Disclosing Party, provide such reasonable assistance as is required by the Disclosing Party to mitigate any damage
caused thereby. 

  

	7	Intellectual Property. 

  

	 	7.1	 ASML will own any and all Intellectual Property (whether arising under the laws of the United States or any other state, country or
jurisdiction, now or hereinafter existing) created by ASML, and any and all work product developed or created by or on behalf of ASML in connection with this Agreement or the Project. For purposes of this Agreement, “Intellectual
Property” means, in any jurisdiction throughout the world: (a) inventions (whether patentable or unpatentable, and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent
disclosures, together with all provisionals, reissuances, continuations, continuations-in-part divisions, revisions, extensions, 

  
 5 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
and reexaminations thereof; (b) marks; (c) copyrightable works, all copyrights, and all website content, and all applications, registrations, and renewals in connection therewith;
(d) mask works and protectable designs, and all applications, registrations, and renewals in connection therewith; (e) trade secrets and confidential business information (including processes, procedures, research and development,
know-how, formulas, algorithms, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, research records, records of inventions, test information, customer and supplier lists, customer
data, pricing and cost information, and business and marketing plans and proposals); (f) software, and all electronic data, databases, and data collections; (g) business processes; (h) all other proprietary and intellectual property
rights; and (i) copies and tangible embodiments of any of the foregoing (in whatever form or medium). 

  

	 	7.2	Each Party will solely and exclusively own all right, title and interest in and to all Intellectual Property that was owned by or licensed to such Party prior to
the Effective Date, or independently of this Agreement. 

  

	8	No Representations and Warranties. 

  

	 	8.1	EACH PARTY HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES WITH RESPECT TO THIS AGREEMENT AND THE PROJECT, WHETHER EXPRESS OR IMPLIED (INCLUDING, BUT NOT
LIMITED TO, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND/OR NON-INFRINGEMENT). EACH PARTY ACKNOWLEDGES THAT IT HAS NOT RELIED ON ANY STATEMENTS, REPRESENTATIONS OR WARRANTIES OF THE OTHER PARTY.

  

	9	Limitations of Liability. 

  

	 	9.1	NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR TO ANY PERSON CLAIMING THROUGH THE OTHER PARTY FOR ANY SPECIAL, PUNITIVE, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY
OR OTHER INDIRECT DAMAGES, ARISING OUT OF OR IN ANY MANNER CONNECTED WITH THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, REGARDLESS OF THE FORM OF ACTION AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF OR OTHERWISE MIGHT HAVE ANTICIPATED THE
POSSIBILITY OF SUCH DAMAGES. 

  

	 	9.2	 THE LIMITATIONS OF LIABILITY IN THIS SECTION 9 SHALL NOT APPLY TO DAMAGES ARISING FROM, RELATING TO, OR BASED ON (i) THE GROSS NEGLIGENCE,
WILLFUL OR INTENTIONAL MISCONDUCT OF A PARTY OR ITS PERSONNEL, (ii) PERSONAL INJURY, DEATH OR DAMAGE TO TANGIBLE PROPERTY CAUSED BY A PARTY OR ITS PERSONNEL, (iii) FRAUDULENT OR CRIMINAL ACTS BY A PARTY OR

  
 6 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
ITS PERSONNEL OR (iv) EITHER PARTY’S BREACH OF ARTICLE 6 HEREUNDER. 

  

	10	General Provisions. 

  

	 	10.1	Construction; Absence of Presumption. 

  

	 	10.1.1	For the purposes of this Agreement, (a) words (including capitalized terms defined herein) in the singular shall be held to include the plural and vice
versa and words (including capitalized terms defined herein) of one gender shall be held to include the other gender as the context requires, (b) the terms “hereof,” “herein” and “herewith” and words of similar
import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including all Appendices) and not to any particular provision of this Agreement, and Article, Section, paragraph, and Appendix references are to the Articles,
Sections, paragraphs, and Appendices to this Agreement, unless otherwise provided, (c) the words “including” and “such as” and words of similar import when used in this Agreement shall mean “including, without
limitation”, and (d) all references to any period of days shall be deemed to be to the relevant number of calendar days unless otherwise provided. 

 

	 	10.1.2	The Parties hereby acknowledge that each Party and its counsel have reviewed and revised this Agreement in good faith and that no rule of construction to the
effect that any ambiguities are to be resolved against the drafting party shall be employed in the interpretation of this Agreement (including all Appendices) or any amendments hereto or thereto. 

 

	 	10.2	Entire Agreement. This Agreement constitutes the entire agreement between the Parties regarding the subject matter hereof, and supersedes all prior agreements,
understandings, negotiations and discussions, whether oral or written, between the Parties regarding such subject matter. 

  

	 	10.3	Amendments and Waivers. No amendment to or modification of this Agreement will be binding unless in writing and signed by a duly authorized representative of
each Party. No waiver of any obligation or condition under this Agreement will be effective unless contained in a written document duly executed by the Party granting such waiver. Any such waiver shall not operate as a waiver of, or estoppel with
respect to, any subsequent or other failure of compliance. 

  

	 	10.4	 Severability. If any provision of this Agreement or the application thereof to any person or circumstance is determined by a court of
competent jurisdiction to be invalid, void, or unenforceable, the remaining provisions hereof or the application of such provision to persons or circumstances or in jurisdictions other than those as to which it has been held invalid or
unenforceable, shall remain in full force and effect and shall in no way be affected, impaired, or invalidated thereby, so 

  
 7 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	
long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any Party. Upon such determination, the Parties shall negotiate in good
faith in an effort to agree upon such a suitable and equitable provision to effect the original intent of the Parties. 

  

	 	10.5	Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between
Funding Partner and ASML, or to constitute one Party as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act
solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other Party. 

 

	 	10.6	Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and without prejudice to any other remedy
referred to in this Agreement or otherwise available under law, equity or otherwise. 

  

	 	10.7	Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

  

	 	10.8	Assignment. This Agreement may not be assigned, in whole or in part, by either Party without the other Party’s prior written consent; provided, that
either Party may assign the Agreement without such consent to an affiliate or a successor to all or substantially all of the assets of the business, whether by sale, merger, operation of law or otherwise. A Party who assigns this Agreement to an
Affiliate will remain responsible for and ensure the performance of any and all obligations of the Affiliate under this Agreement. 

  

	 	10.9	Notices. All notices or other communications under this Agreement shall be in writing and shall be deemed to be duly given when (a) delivered in
person or (b) deposited in the registered mail or private express mail, postage prepaid, addressed as follows: 

 If to Funding Partner, to: 
 Unless otherwise agreed in writing by the Parties, all
notices to Funding Partner regarding this Agreement will include a copy to the attention of Funding Partner’s *** and to the Funding Partner *** as follows: 
 Intel Corporation 
 2200 Mission College Blvd. 

Santa Clara, CA 95054 
 with a copy to: 
 *** and *** 

  
 8 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

 If to ASML to: 
 *** 
 *** 
 *** 
 ASML Netherlands B.V. 

De Run 6501, 5504 DR Vehdhoven 
 PO Box 324, 5500 AH Veldhoven 
 The Netherlands 

Any Party may, by notice to the other Party, change the address to which such notices are to be given. 

 

	 	10.10	Export Control. Neither Party shall export or re-export, directly or indirectly, any technical information disclosed hereunder or direct product thereof
to any destination prohibited or restricted by the export control regulations of the Netherlands and the United States, including the U.S. Export Administration Regulations, without prior authorization from the appropriate governmental authorities.

  

	 	10.11	Dispute Resolution. In the event of any dispute under this Agreement, the senior management of each Party will meet to resolve the dispute. If the dispute
is not resolved by senior management within thirty (30) days after escalation, either Party may make a written request for formal dispute resolution and specify therein the scope of the dispute. Within thirty (30) days after such written
notification, the Parties will meet for one day with an impartial mediator and consider dispute resolution alternatives other than litigation. If an alternative method of dispute resolution is not agreed upon within thirty (30) days after the
one day mediation, either Party may pursue any right or remedies available under law, in equity or under this Agreement. Notwithstanding the foregoing, neither Party shall be precluded at any time from seeking injunction relief against the other
Party. 

  

	 	10.12	Force Majeure. No Party shall be deemed in default of this Agreement to the extent that any delay or failure in the performance of its obligations under this
Agreement results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts of civil or military authority, embargoes, epidemics, war, riots, insurrections, fires, explosions, earthquakes, floods,
unusually severe weather conditions, labor problems or unavailability of parts, or, in the case of computer systems, any failure in electrical or air conditioning equipment. In the event of any such excused delay, the time for performance shall be
extended for a period equal to the time lost by reason of the delay. 

  
 9 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

	 	10.13	Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute a
single instrument. 

  

	 	10.14	Headings. Any section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. 

  

	 	10.15	Applicable Law and Forum. This Agreement shall be construed and interpreted in accordance with the laws of the State of Delaware, excluding
Delaware’s conflicts of law provisions. The provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. All disputes and litigation arising out of or relating to this
Agreement, including without limitation matters connected with its performance, shall be subject to the exclusive jurisdiction of the courts of the State of Delaware or of the Federal Courts sitting therein. The parties hereby irrevocably submit to
the personal jurisdiction of such courts and irrevocably waive all objections to such venue. 

[Signature page follows] 

  
 10 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, this Agreement has been signed on behalf of the Parties hereto by persons duly
authorized in that behalf: 
  

									
	ASML Holding N.V.	 		 	Intel Corporation
					
	SIGNATURE:	 	 /s/ Eric Meurice
	 		 	SIGNATURE:	 	 /s/ Brian M. Krzanich

					
	NAME:	 	 Eric Meurice
	 		 	NAME:	 	 Brian M. Krzanich

					
	TITLE:	 	 Chief Executive Officer, Chairman of Management Board
	 		 	TITLE:	 	 Senior Vice President, Chief Operating Officer

					
	DATE:	 	 July 9, 2012
	 		 	DATE:	 	 July 9, 2012

				
	ASML Holding N.V.	 		 		 	
					
	SIGNATURE:	 	 /s/ Peter Wennink
	 		 		 	
					
	NAME:	 	 Peter Wennink
	 		 		 	
					
	TITLE:	 	 Chief Financial Officer, Member of the Management Board
	 		 		 	
					
	DATE:	 	 July 9, 2012
	 		 		 	

 SIGNATURE PAGE TO EUV NRE FUNDING AGREEMENT 

  
 11 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

 APPENDIX 1 

ROADMAP 
 Below
roadmaps are indicative and can be changed in ASML’s discretion, respecting the agreed upon Milestones. 
  

 

  
 12 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

 APPENDIX 2 
 PROJECT EXPENDITURE ESTIMATE 
 This Appendix 2 stipulates the process related to the
estimation of the Project Expenditures and the limited *** for temporary *** and it supersedes and has precedent over the terms set out in the EUV NRE Funding Agreement (“Agreement”). Project Expenditures due from Funding Partner are to be
used only to fund the projects outlined below for EUV, with use of Funding Partner funds and identified in the Schedule 1 below for EUV development. 
 Availability of any funding from Funding Partner is contingent upon the Additional Closing and Funding Partner is not responsible for any funds absent such Additional Closing. 

In the event that the Additional Closing does not occur, the Parties may enter in good faith discussions in order to renegotiate a new EUV NRE Funding
Agreement, and the parties will meet to renegotiate those aspects of the Commercial Agreement related to the delivery of EUV tools. 
 1.
Estimation: 
 ASML will update every year of the funding period and communicate before the end of each year, the updated estimate covering
until the end of the funding period and an explanation of the changes. ASML’s preliminary estimate is as follows in Schedule 1 below. 

ASML agrees to fund the EUV portion of the Project Expenditures in accordance with the annual amounts set out below in Schedule 1. 

SCHEDULE 1 
 Project EUV

  

													
	 	  	2013	 	2014	 	2015	 	2016	 	2017	 	Totals 2013-2017
	 EUV High NA
	  	***	 	***	 	***	 	***	 	***	 	***
	 EUV Source
	  	***	 	***	 	***	 	***	 	***	 	***
	 EUV 300mm
	  	***	 	***	 	***	 	***	 	***	 	***
	 EUV 450mm
	  	***	 	***	 	***	 	***	 	***	 	***
	 Totals (EUV 300mm, 450mm, EUV High)
	  	***	 	***	 	***	 	***	 	***	 	***
							
	 NRE Suppliers
	  	***	 	***	 	***	 	***	 	***	 	***
							
	 Total EUV incl. NRE Suppliers
	  	***	 	***	 	***	 	***	 	***	 	***
							
	 Agreed Funding
	  	***	 	***	 	***	 	***	 	***	 	***
	 Resulting % yearly spread
	  	***	 	***	 	***	 	***	 	***	 	***
	 Resulting estimated Yearly Funding
	  	***	 	***	 	***	 	***	 	***	 	***

 The Parties acknowledge that the numbers in the table in Schedule 1 are illustrative and that Funding Partner agreed to a
total of €276,000,000 as set out in article 2.1 of this Agreement. 
 Within 3 months of signature of the Agreement, ASML and the Funding
Partner will agree on a final update of this estimate, which will serve as the “Original Estimate”. ASML will fund at least €*** split as follows €*** for EUV High NA, €*** for EUV source, €*** for EUV 300mm

  
 13 

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately
with the Securities and Exchange Commission. 
  

 
and *** for EUV 450mm, and such amounts are not *** or *** in any way, including upon the terms of any other agreement entered into by the Parties, including any agreements entered into
contemporaneously with this Agreement. 
 Concurrently with the confirmation of the Original Estimate, and within 3 months of signature of the
Agreement, ASML and the Funding Partner will agree on a set of action milestones, leading to a set of delivery milestones, enabled by the funding estimate. These milestones will constitute the “Original Milestone Plan”. The EUV project
will be solely monitored through funding milestones through 20*** and EUV milestones will be mutually agreed and amended to the Milestone Plan by December 31, 20*** such that the EUV program will be monitored through delivery milestones
beginning January 1, 20***. 
 The Project Expenditure estimate and the Milestone Plan will be updated yearly in good faith through mutual
discussions with Funding Partner. Annual estimates for ASML’s Project Expenditures in each calendar year for EUV High NA, EUV source, and EUV 300mm in the Original Estimate may be adjusted +/-***% from the Original Estimate, and beyond ***%
will require mutual agreement between ASML and Funding Partner. 
 2. Rights of ***: 
 ASML and Funding Partner will create a Technical Review Board” (TRB) including only technical personnel designated by each Party and responsible for creating and monitoring the Milestone
Plan. Unless otherwise agreed in writing between the Parties, ASML agrees to invest in a given year up to a minimum of ***% of the Project Expenditures stipulated in *** for the EUV Program.

Notwithstanding Section *** in the Agreement, Funding Partner *** are subject to the following additional ***:, if (i) ASML *** to *** the ***%
threshold of the *** for EUV on a given year, and (ii) *** to *** a milestone under the Milestone Plan then Funding Partner may *** its *** until *** by ASML. Prior to *** any *** to ASML, Funding Partner will give ASML a minimum of ***
(***) *** prior notice of its *** to ***, during which time ASML will provide Funding Partner with a *** of its *** to *** the requirements under the Milestone Plan. The TRB will review the *** of the *** milestone. If the TRB determines that
ASML has made a *** to *** on the Milestone, and the *** is not based on lack of ***, and if the TRB determines the *** were ***, Funding Partner will *** any *** to ASML. 
 Notwithstanding any delays by ASML, Funding Partner will abide by its commitment as stipulated in the Milestone Plan as determined by the TRB, including but not limited to the stipulated technical
support, specification agreement, purchase order issue, etc,. 
 3. Notwithstanding Sections 6, Confidentiality, and ***, ***, ASML and Funding
Partner will *** a *** setting out the *** related to the ***, ***, ***, and *** for *** provided by and *** funded by Funding Partner under this Agreement. 

  
 14EX-4.34

 Exhibit 4.34 
 Shareholder Agreement 
 relating to 

ASML Holding N.V. 
 Between 
 Intel Holdings B.V. 

and 

Intel Corporation 
 and 
 Stichting Administratiekantoor MAKTSJAB 

and 

ASML Holding N.V. 
 Dated 12 September 2012 

 Contents 
  

									
	Section	  	Page	 
			
	1	  	 INTERPRETATION
	  	 	5	 
			
	2	  	 SHARES HELD BY STICHTING; VOTING MATTERS
	  	 	5	 
				
		  	2.1	  	 Stichting Shares
	  	 	5	 
				
		  	2.2	  	 Attendance at General Meeting by Stichting
	  	 	5	 
				
		  	2.3	  	 Voting with Respect to Stichting Shares
	  	 	6	 
				
		  	2.4	  	 Voting Procedures
	  	 	8	 
			
	3	  	 LIMITATIONS ON SHAREHOLDING
	  	 	8	 
				
		  	3.1	  	 Acquisition of Shares; Standstill
	  	 	8	 
				
		  	3.2	  	 Permitted Exceptions to Standstill
	  	 	9	 
				
		  	3.3	  	 Exchange of Depositary Receipts for Shares
	  	 	10	 
				
		  	3.4	  	 Notification Ownership
	  	 	11	 
				
		  	3.5	  	 4.99% outside Stichting
	  	 	12	 
			
	4	  	 LOCK-UP
	  	 	13	 
				
		  	4.1	  	 Lock-Up Period
	  	 	13	 
				
		  	4.2	  	 Permitted Exceptions to Lock-Up
	  	 	13	 
				
		  	4.3	  	 Hostile Offer
	  	 	14	 
				
		  	4.4	  	 In Excess of Maximum Shareholding
	  	 	14	 
			
	5	  	 NOTICE AND INFORMATION RIGHTS
	  	 	15	 
				
		  	5.1	  	 Event Notification
	  	 	15	 
				
		  	5.2	  	 Financial Information
	  	 	15	 
			
	6	  	 TRANSFERS OF SHARES
	  	 	16	 
				
		  	6.1	  	 Limited Transferability
	  	 	16	 
				
		  	6.2	  	 Max 4% Market Sales
	  	 	17	 
				
		  	6.3	  	 Limited Transfer to Certain Competitors or Customers
	  	 	17	 
				
		  	6.4	  	 Proceeds of Transfer
	  	 	17	 
			
	7	  	 DURATION AND TERMINATION
	  	 	17	 
				
		  	7.1	  	 Term
	  	 	17	 
				
		  	7.2	  	 Termination
	  	 	18	 
				
		  	7.3	  	 Survival
	  	 	18	 
			
	8	  	 MISCELLANEOUS
	  	 	18	 
				
		  	8.1	  	 Further assurances; No Inconsistent Agreements
	  	 	18	 
				
		  	8.2	  	 Entire agreement
	  	 	19	 
				
		  	8.3	  	 No assignment
	  	 	19	 
				
		  	8.4	  	 Waiver
	  	 	19	 
				
		  	8.5	  	 Amendment
	  	 	19	 

  
 2 / 26

									
		  	8.6	  	 Third Party Rights
	  	 	20	 
				
		  	8.7	  	 Rescission; Remedies
	  	 	20	 
				
		  	8.8	  	 Costs
	  	 	20	 
				
		  	8.9	  	 Language
	  	 	20	 
				
		  	8.10	  	 Notices
	  	 	20	 
				
		  	8.11	  	 Invalidity
	  	 	23	 
				
		  	8.12	  	 Counterparts
	  	 	23	 
				
		  	8.13	  	 Dispute resolution
	  	 	24	 
				
		  	8.14	  	 Governing law
	  	 	26	 
			
	9	  	 INVESTOR PARENT GUARANTEE
	  	 	26	 

  

			
	 Schedules

		
	Schedule 1	  	Definitions and Interpretations
		
	Schedule 2	  	Conditions of Administration (including Stichting Articles)
		
	Schedule 3	  	Specified Companies [omitted]
		
	Schedule 4	  	Specified Customers [omitted]

  
 3 / 26

 Shareholder Agreement 
 THE UNDERSIGNED: 
  

	(1)	Intel Holdings B.V., a private limited liability company, incorporated in the Netherlands, with corporate seat in Amsterdam, and address at Capronilaan
37, 1119 NG, Schiphol-Rijk, the Netherlands, and trade register number 34361666 (“Investor”); 

  

	(2)	Intel Corporation, a Delaware corporation, with address at 2200 Mission College Blvd, Santa Clara, 95054 California, United States of America,
(“Investor Parent”); 

  

	(3)	Stichting Administratiekantoor MAKTSJAB, a foundation incorporated in the Netherlands, with corporate seat in Amsterdam, and address at Claude Debussylaan
24, 1082 MD Amsterdam, the Netherlands, and trade register number 56002386 (the “Stichting”); and 

  

	(4)	ASML Holding N.V., a limited liability company incorporated in the Netherlands, with corporate seat in Veldhoven and address at De Run 6501, 5504 DR,
Veldhoven, the Netherlands, and trade register number 17085815 (the “Company”); 

 WHEREAS: 

 

	(A)	The Company is a leading manufacturer of advanced technology systems for the semiconductor industry. It is continually developing new systems, devoting a
significant portion of its financial resources to research and development. To support the continuous development of new technologies, the Company and Investor Parent entered into two NRE Agreements on 9 July, 2012, providing for Investor
Parent funding a portion of the Company’s expenditures under its non-recurring engineering program. 

  

	(B)	On 9 July, 2012, Investor Parent and the Company entered into an investment agreement (the “Investment Agreement”) relating to the issuance
of Ordinary Shares (as defined herein) of the Company to the Stichting and the issuance of corresponding Depositary Receipts to Investor Parent or its Investor Designee (as defined in the Investment Agreement), pursuant to which Investor acquired
Depositary Receipts in return for the consideration stated in the Investment Agreement. As a condition to the Investment Agreement, Investor and the Company will become a party to this Agreement. 

 

	(C)	 Investor is an indirect wholly-owned subsidiary of Investor Parent. Pursuant to an assignment and assumption agreement dated as of 9 July
2012, Investor 

  
 4 / 26

	 	
Parent assigned all of its rights and obligations with respect to the purchase of the subject shares as set forth under the Investment Agreement to Investor. 

 

	(D)	Parties now wish to enter into this Agreement in order to set out the agreed terms and conditions for Investor’s ownership of Shares (as defined herein).

  

	1	INTERPRETATION 

 In this
Agreement, unless the context otherwise requires, the definitions and provisions of Schedule 1 (Definitions and Interpretations) shall apply throughout. 
  

	2	SHARES HELD BY STICHTING; VOTING MATTERS 

  

	2.1	Stichting Shares 

  

	2.1.1	In exchange for the consideration paid by Investor to the Company, the Company has issued 62,977,877 Ordinary Shares to the Stichting by way of administration (ten
titel van beheer), and the Stichting in turn has issued a corresponding number of Depositary Receipts to Investor. 

  

	2.1.2	All Stichting Shares shall be held in accordance with the Conditions of Administration and with due observance of the Stichting Articles. The Stichting is not allowed
to amend its articles nor the Conditions of Administration nor to dissolve the Stichting without the prior consent of the Parties other than in accordance with this Agreement. In case of a conflict between any other provisions of this Agreement and
the Conditions of Administration or the Stichting Articles, (i) the conflicting provisions of this Agreement shall prevail to the extent permitted by Law and (ii) the Parties shall take any action which may be necessary or appropriate in
order to amend the Conditions of Administration or the Stichting Articles to be in accordance with such other provisions in this Agreement, any such amendment to be subject to the approval of the Parties. 

 

	2.2	Attendance at General Meeting by Stichting 

  

	2.2.1	As long as the Stichting holds Stichting Shares, the Stichting shall be authorised: 

 

	 	(a)	to attend General Meetings and sign the attendance list; and 

  

	 	(b)	to speak at General Meetings about any matters that come up for discussion, to the extent that the Stichting is instructed to do so, or represented, by Investor or its
Affiliates Owning Depositary Receipts, in accordance with Section 2.3. 

  
 5 / 26

	2.2.2	The Stichting shall not vote on the Stichting Shares in the General Meeting with regard to any proposals made to the General Meeting unless the Stichting is instructed
to do so by Investor or its Affiliates Owning Depositary Receipts or will be represented by Investor or its Affiliates Owning Depositary Receipts in accordance with Section 2.3.3. 

 

	2.3	Voting with Respect to Stichting Shares 

  

	2.3.1	Upon convocation by the Company of a General Meeting, the Company shall promptly notify the Stichting thereof. 

 

	2.3.2	The Stichting shall provide to Investor and its Affiliates Owning Depositary Receipts promptly, but in no event later than two (2) Business Days after receipt
thereof, a copy of such notice and any other documents received therewith or related thereto. 

  

	2.3.3	The Stichting shall provide to Investor and its Affiliates Owning Depositary Receipts promptly upon convocation of any General Meeting, but in any event within two
(2) Business Days after receipt of written request by Investor or its Affiliates Owning Depositary Receipts, a proxy with respect to the Stichting Shares and will make the relevant filings with the Company to allow Investor and such Affiliates
to vote the Stichting Shares on (1) all matters, in the event that a Suspension Event occurs and is continuing regardless of the items on the agenda for such meeting or (2) in the absence of a continuing Suspension Event, on the following
matters, when the agenda for such General Meeting contains one or more of them: 

  

	 	(i)	any resolution to issue Shares or to grant rights to subscribe for Shares or to designate the Management Board as the authorized body to issue Shares or grant rights to
subscribe for Shares, except if such resolution relates to less than twenty-five per cent (25%) (on an aggregate basis with all other amounts approved by resolution in the twelve (12)-month period preceding such General Meeting) of the issued
and outstanding Shares at the date of such resolution; 

  

	 	(ii)	any resolution to restrict or exclude, or grant authority to the Management Board or other authorized body to restrict or exclude, pre-emption rights accruing to
shareholders of the Company in connection with any issue of Shares as described under subsection (i) above; 

  

	 	(iii)	 any resolution to authorize the Management Board to repurchase twenty-five per cent (25%) (on an aggregate basis with all other amounts approved
by resolution in the twelve 

  
 6 / 26

	 	
(12) month period preceding such General Meeting) or more of the issued and outstanding Shares at the date of such resolution; 

 

	 	(iv)	any resolution to approve resolutions of the Management Board regarding a significant change in the identity or nature of the Company or its business within the meaning
of article 2:107(a) of the Dutch Civil Code, including but not limited to: 

  

	 	1.	the transfer (including by way of exclusive license) of all or substantially all of the business or assets of the Company and its subsidiaries to a Third Party;

  

	 	2.	the establishment or cancellation of any long-lasting co-operation by the Company or any of its subsidiaries with any other Person; provided, that such
co-operation or the cancellation thereof is of essential importance to the Company; and 

  

	 	3.	the acquisition or disposition of an interest in the capital of a Person or the assets thereof having a value of at least one-third (1/3) of the sum of all assets
of the Company, as determined in accordance with the most recently adopted consolidated balance sheet of the Company prior to the General Meeting; 

  

	 	(v)	any resolution to amend the articles of association of the Company that would (i) materially affect the specific voting rights set forth in 2.3.3 of this
Agreement; (ii) materially affect the identity or nature of the Company or its business; or (iii) disproportionately (or uniquely) and adversely affect the rights or benefits attached to or derived from the Shares Owned by Investor and its
Affiliates as an investor in the share capital of the Company as compared to the other holders of Shares of the same class as the Stichting Shares. 

  

	 	(vi)	any resolution to dissolve the Company; or 

  

	 	(vii)	any resolution to merge or demerge the Company resulting in a significant change in identity or nature of the Company or its business. 

  
 7 / 26

	2.4	Voting Procedures 

  

	2.4.1	Upon receipt of a proxy in accordance with Section 2.3.3, Investor and its Affiliates Owning Depositary Receipts may either (i) use such proxy to vote the
Stichting Shares, or (ii) instruct the Stichting in writing with respect to the Stichting Shares, to speak at a General Meeting and to exercise their voting rights, in each case, in favour of or against any applicable proposed resolution at the
applicable General Meeting. 

  

	2.4.2	 Instructions made to the Stichting as referred to under Section 2.4.1 will become irrevocable on the second (2nd) Business Day prior to the relevant General Meeting.
Instructions or amendments to instructions received by the Stichting on or after the Business Day prior to the General Meeting shall not be accepted by the Stichting. Instructions as referred to under Section 2.4.1 must be sent in accordance
with Section 8.10. 

  

	2.4.3	In the event Investor and its Affiliates Owning Depositary Receipts wish to vote in any General Meeting, or instruct the Stichting to vote at such General Meeting
Investor, or each of Investor and its Affiliates Owning Depositary Receipts shall, no later than two (2) weeks before the date of such General Meeting, send written notice to the Company which notice will include the number of Shares Investor
and each Affiliate Owning Depositary Receipts believes it has the right to vote or instruct voting on in the General Meeting and each proposed resolution where Investor and its Affiliates Owning Depositary Receipts believe they have such a right
together with a reasonably detailed description of the basis therefor (a “Voting Notice”). Within two (2) Business Days after receipt of a Voting Notice, the Company shall send written notice to Investor and its Affiliates
Owning Depositary Receipts including either (i) a confirmation that the Company agrees that Investor and its Affiliates Owning Depositary Receipts have the rights to vote and instruct the Stichting, as the case may be, on the Shares as set out
in the Voting Notice, or (ii) a statement that the Company believes Investor and its Affiliates Owning Depositary Receipts may not vote or provide instructions with respect to such number of Shares as specified in the statement and/or, with
respect to such resolutions as specified in the statement pursuant to this Agreement, in each case together with a reasonably detailed description of the basis therefor. 

 

	3	LIMITATIONS ON SHAREHOLDING 

  

	3.1	Acquisition of Shares; Standstill 

  

	3.1.1	 As of the date of this Agreement until the date that is the earlier of (i) the sixth (6th) anniversary of the date of this Agreement and
(ii) the occurrence of a Termination Event (until such earlier date, the “Standstill Period”), Investor and its Affiliates shall not, in the aggregate, without the prior written approval of

  
 8 / 26

	 	
the Company, in any manner acquire, agree to acquire, or make any proposal or offer to acquire, directly or indirectly, Ownership in excess of the Maximum Shareholding except as provided in
Section 3.2. 

  

	3.1.2	Investor and its Affiliates shall transfer all Shares Owned by them to the Stichting in exchange for Depositary Receipts within ten (10) days of acquiring such
Shares, except to the extent that Investor and its Affiliates would be permitted to exchange such Depositary Receipts for Shares or that Investor or its Affiliates would be permitted to retain such Shares pursuant to Section 3.3 or 3.5.

  

	3.2	Permitted Exceptions to Standstill 

  

	3.2.1	The Standstill Period shall be suspended upon the occurrence and during the continuance of any Suspension Event as provided in this Section 3. The Company and
Investor shall notify each other and the Stichting of any Suspension Event or the termination thereof in accordance with Section 5, to the extent they are aware of it. 

 

	3.2.2	In the event of a Third Party Acquisition, Investor and its Affiliates shall be permitted to in the aggregate acquire, agree to acquire, or make any proposal or offer
to acquire, directly or indirectly, Ownership in excess of the Maximum Shareholding up to the amount Owned by the Third Party that engaged in such Third Party Acquisition (as such amount may be identified in the Company’s notice or the Third
Party’s disclosure of its Ownership in a filing with the SEC or the AFM or otherwise) until Investor receives the Company’s notice of the termination of the Suspension Event in accordance with Section 5. Upon receipt by Investor of
such notice, the limitations set forth in Section 3.1 shall no longer be suspended and shall apply to Investor and its Affiliates except as provided in Section 3.2.4. 

 

	3.2.3	 In the event of a Third Party Offer or an announcement by the Company of its intention to enter into a Change of Control Transaction, Investor and its
Affiliates shall be permitted to acquire or to make a competing offer to acquire Shares not Owned by Investor or its Affiliates, except that if the percentage of the Disclosed Shares Outstanding that are sought to be acquired in a Third Party Offer
is less than thirty per cent (30%), Investor and its Affiliates may in the aggregate not acquire more than the percentage sought to be acquired in such Third Party Offer; provided that such right to acquire or to make an offer shall terminate
upon receipt by Investor of notice in accordance with Section 5 that the Third Party Offer has been withdrawn or that the Third Party Offer or announced Change of Control Transaction has terminated, as the case may be, at which time the
limitations set forth in Section 3.1 shall no longer be suspended and shall apply to Investor and its Affiliates as if no Third Party Offer or announcement of intention to enter into a Change of Control

  
 9 / 26

	 	
Transaction had occurred; and provided, further, that none of the limitations set forth in Section 3.1 are intended to limit or prohibit Investor and its Affiliates from
completing any acquisition or competing offer commenced pursuant to Section 3.2.2 or Section 3.2.3 prior to receipt of the Company’s notice of termination of the Suspension Event. 

 

	3.2.4	If, after the termination of such Suspension Event, Investor and its Affiliates in the aggregate Own as a result of any acquisition or any competing offer made pursuant
to Section 3.2.2 or Section 3.2.3, Shares in excess of nineteen-and-nine-tenths per cent (19.9%) of the Disclosed Shares Outstanding, Investor and its Affiliates shall be permitted to retain such Ownership. In such case, the
“Maximum Shareholding” will be deemed to be the lower of (a) such percentage of the Disclosed Shares Outstanding Owned in the aggregate by Investor and its Affiliates immediately following such acquisition or competing offer
and (b) in the case of any subsequent divestment of Shares by Investor or its Affiliates, the percentage Ownership held in the aggregate by Investor and its Affiliates immediately following such divestment, but in no event less than
nineteen-and-nine-tenths per cent (19.9%) of the Disclosed Shares Outstanding. For the avoidance of doubt, the “Maximum Shareholding” may be increased again pursuant to Section 3.2.2 or Section 3.2.3, as applicable,
in the event of any other Suspension Event. 

  

	3.2.5	Any Shares acquired by Investor and its Affiliates as allowed pursuant to the occurrence of a Suspension Event in accordance with Section 3.2 and continued to be
Owned by Investor and its Affiliates following termination of a Suspension Event shall be deposited in the Stichting in exchange for Depositary Receipts, in accordance with Section 3.1.2, to the extent such Shares in the aggregate exceed the
four-and-ninety-nine-one hundredths per cent (4.99%) holding limitation under Section 3.5. 

  

	3.3	Exchange of Depositary Receipts for Shares 

  

	3.3.1	Subject to Section 3.3.2 and Section 3.3.3, after the termination of the Lock-Up Period, Investor and its Affiliates may at any time exchange Depositary
Receipts for Shares so long as such exchange does not cause the aggregate of Shares held by Investor and its Affiliates outside the Stichting, to exceed two per cent (2%) of the Disclosed Shares Outstanding (whereby any Shares held by Investor
and its Affiliates outside the Stichting shall reduce the amount that may be exchanged accordingly). After the Standstill Period, Investor and its Affiliates may acquire Shares so long as the total aggregate number of Shares Owned by Investor and
its Affiliates and not deposited with the Stichting is less than 4.99% of the Disclosed Shares Outstanding and all other Shares shall be deposited with the Stichting. 

 

	3.3.2	 Notwithstanding any other provision in this Section 3.3, Investor and its

  
 10 / 26

	 	
Affiliates may exchange their Depositary Receipts for Shares in order to tender such Shares to the offeror in connection with a Third Party Offer or instruct the Stichting to tender the Stichting
Shares as to which Investor holds Depositary Receipts in connection with such Third Party Offer. 

  

	3.3.3	All Depositary Receipts will be exchanged for the Shares corresponding to such Depositary Receipts upon the earliest to occur of: 

 

	 	(a)	the first date that the aggregate of the Stichting Shares and the aggregate of Shares Owned by Investor and its Affiliates outside of the Stichting no longer represent
at least two per cent (2%) of the Disclosed Shares Outstanding; and 

  

	 	(b)	the date of notification by the Company of an aggregate Ownership of the Other Investors and their respective Affiliates, or deemed aggregate Ownership of the Other
Investors and their respective Affiliates, in each case in accordance with Section 3.4.2, which together with the aggregate Ownership of Investor and its Affiliates at the time of such notification represents less than five per cent
(5%) of the Disclosed Shares Outstanding; and 

  

	 	(c)	a Termination Event. 

  

	3.3.4	Each of the Company and the Stichting shall use commercially reasonable best efforts to permit the prompt and timely exchange of Depositary Receipts for Shares for
delivery by Investor and its Affiliates as contemplated in this Section 3.3, including in connection with a sale or Transfer thereof, and in all events, in a manner and in such period of time as to enable Investor and its Affiliates to comply
with their obligations to deliver the Shares under applicable Law. 

  

	3.3.5	Subject to Section 7.2.2(a), if, at any time subsequent to an exchange of Depositary Receipts for Stichting Shares in accordance with Section 3.3.3(a) or
(b) of this Agreement, the aggregate of Shares Owned by Investor and its Affiliates represents more than two per cent (2%) of Disclosed Shares Outstanding, Investor and its Affiliates shall be obligated to transfer all of their Shares in
excess of four-and-ninety-nine-one hundredths per cent (4.99%) of the Disclosed Shares Outstanding to the Stichting in exchange for Depositary Receipts. 

 

	3.4	Notification Ownership 

  

	3.4.1	 During any period in which the public registers held by the AFM do not reflect that Investor and its Affiliates together or any Other Investor and its
respective Affiliates together own five per cent (5%) or more of the Disclosed Shares Outstanding, (i) Investor or Investor Parent may request the Company an 

  
 11 / 26

	 	
aggregate together of no more than ten (10) times in any twelve (12) month period to provide Investor with a certified specification of the aggregate Ownership of the Other Investors
and their respective Affiliates provided that with such request Investor shall provide the Company with a certified specification of its and its Affiliates’ Ownership and (ii) the Company may request Investor or Investor Parent an
aggregate together of no more than ten (10) times in any twelve (12) month period to provide the Company with a certified specification of the Ownership of Investor and its Affiliates. 

 

	3.4.2	The Company shall provide Investor or Investor Parent with the information requested by Investor or Investor Parent pursuant to Section 3.4.1, certified by each of
the relevant Other Investors in respect of its and its Affiliates’ Ownership to be true and correct as of the date of such certification, as soon as practicable, but in any event within twenty (20) Business Days from the date of receipt of
such request, failing which the Other Investor or Other Investors and their respective Affiliates in respect of which no certified information is provided shall for the purpose of Section 3.3.3(b) be deemed to Own no Shares.

  

	3.4.3	Investor shall provide the Company with the information requested by the Company pursuant to Section 3.4.1, certified by it to be true and correct as of the date
of such certification, as soon as practicable, but in any event within ten (10) Business Days from the date of receipt of such request. 

  

	3.4.4	In the event of a request for information by Investor, Investor Parent or the Company pursuant to Section 3.4.1, the Company may request the Stichting, and the
Stichting shall be obliged, to provide the Company with a specification of the number of Depositary Receipts Owned by Investor and its Affiliates. 

  

	3.4.5	The Company shall be permitted to disclose the information provided by Investor to the Company pursuant to Section 3.4.3 to each of the Other Investors.

  

	3.4.6	The Company shall as soon as practicable, but in any event within three (3) Business Days from the date of receipt of the information provided by it to Investor
pursuant to Section 3.4.2 and the information provided by Investor to the Company pursuant to Section 3.4.3 publish such information on its website. 

 

	3.5	4.99% outside Stichting 

For the avoidance of doubt, Parties agree that: 
  

	 	(a)	 Investor and its Affiliates may acquire Shares from any Third Party without depositing such Shares with the Stichting to the extent that the aggregate
of Shares Owned by Investor and its Affiliates not deposited 

  
 12 / 26

	 	
with the Stichting, does not exceed 4.99% of the Disclosed Shares Outstanding (the “Outside Shares”); 

 

	 	(b)	for the purpose of the standstill provisions of Section 3.1, the Outside Shares shall be included in the calculation of the number of Shares Owned by Investor and
its Affiliates; 

  

	 	(c)	the Lock-up provisions of Section 4.1 shall not apply to the Outside Shares, except as specified in Section 4.3; and 

 

	 	(d)	Investor and its Affiliates shall be permitted to vote any Outside Shares in a General Meeting, except as provided in Section 4.4.1; and 

 

	 	(e)	Shares Owned by one or more Non-Controlled Employee Benefit Plans that, in the aggregate, amount to less than one per cent (1%) of the Disclosed Shares Outstanding
shall not be deemed Shares Owned by Investor or its Affiliates and shall not be subject to the provisions hereof. 

  

	4	LOCK-UP 

  

	4.1	Lock-Up Period 

  

	4.1.1	Except for any Transfer explicitly permitted or required under this Agreement, as of the date of this Agreement until the earliest of (i) 12 March 2015,
(ii) the termination of the NRE Agreements or (iii) a Termination Event (the “Lock-Up Period”), neither Investor nor any of its Affiliates shall, without the prior written approval of the Company, in any manner, directly
or indirectly, sell, assign, donate, gift, pledge, hypothecate, dispose of or transfer, in whole or in part to any Person (each such action, a “Transfer”), agree to Transfer, or make any proposal or offer to Transfer, directly or
indirectly, or direct the Stichting to Transfer any Shares or Depositary Receipts issued to Investor or the Stichting pursuant to the Investment Agreement. 

 

	4.1.2	After termination of the Lock-up Period, Investor and its Affiliates Owning Depositary Receipts may direct the Stichting to Transfer any Stichting Shares to any Person,
provided that such Transfer is in compliance with Sections 4.3, 6.2 and 6.3. 

  

	4.2	Permitted Exceptions to Lock-Up 

 Notwithstanding Sections 4.1, 6.2 and 6.3 and subject to Section 4.3, in the event of a Third Party Offer, Investor and its Affiliates shall be permitted to agree to tender and to tender or

  
 13 / 26

 
otherwise Transfer any or all of the Shares held by Investor and its Affiliates and to direct the Stichting to tender or otherwise Transfer any or all of the Stichting Shares to the offeror, and
the Lock-Up Period shall be deemed not to be in effect so long as the Third Party Offer continues and through the consummation or withdrawal thereof; provided, that after the Third Party Offer is withdrawn or terminates, the limitations set
forth in Section 4.1.1 shall again apply. 
  

	4.3	Hostile Offer 

  

	4.3.1	In the event of a Third Party Offer, or a publicly announced intention to make a Third Party Offer, which offer is not recommended to be accepted by the Supervisory
Board or Management Board (a “Hostile Offer”) Investor and its Affiliates shall not until the earlier of (i) completion or withdrawal of such Third Party Offer; (ii) recommendation of such Third Party Offer by the
Supervisory Board or Management Board or (iii) unless the Company has notified Investor that the Supervisory Board or the Management does not recommend or intend to recommend the relevant Third Party Offer, the lapse of 15 Business Days from
the first public announcement of such Third Party Offer or intention to make such Third Party Offer: 

  

	 	(a)	Transfer, agree to Transfer, or make any proposal or offer to Transfer, directly or indirectly, any Shares or Depositary Receipts or direct the Stichting to Transfer
any Stichting Shares to any Third Party; or 

  

	 	(b)	make any public statement of support of such Hostile Offer, 

 provided that Investor and its Affiliates shall be permitted to tender Shares, and to direct the Stichting to tender Shares, into such Hostile Offer either (x) at the last day of the acceptance
period for such Hostile Offer, if no post-acceptance period for such Hostile Offer has been announced or (y) during the post-acceptance period of such Hostile Offer, if a post-acceptance period for such Hostile Offer has been announced.

  

	4.3.2	Prior to any public announcement of an intention to make a Third Party Offer, Investor and its Affiliates shall not agree to tender or direct the Stichting to tender
any Shares under any Third Party Offer, or otherwise Transfer any Shares or Depositary Receipts to any Person known to Investor or such Affiliate to be intending to make a Third Party Offer imminently, other than subject to recommendation of such
Third Party Offer by the Supervisory Board or the Management Board. 

  

	4.4	In Excess of Maximum Shareholding 

  

	4.4.1	 If Investor or the Company becomes aware of Investor and its Affiliates, in the aggregate, Owning Shares in excess of the Maximum Shareholding, it
shall notify the other Parties. Investor and its Affiliates shall not vote on the Shares 

  
 14 / 26

	 	
they Own in excess of the Maximum Shareholding. 

  

	4.4.2	In the event Investor and its Affiliates, in the aggregate, Own Shares in excess of the Maximum Shareholding at any time during the Lock-Up Period, Investor and its
Affiliates shall dispose such number of Shares by which their Ownership exceeds the Maximum Shareholding within thirty (30) days from the date of the notice pursuant to Section 4.4.1, unless any action of the Company has caused the
Investor and its Affiliates, in the aggregate, to Own Shares in excess of the Maximum Shareholding, in which event such disposal may be completed within twelve (12) months from the date of such notice. 

 

	5	NOTICE AND INFORMATION RIGHTS 

  

	5.1	Event Notification 

 For
so long as Investor or any of its Affiliates holds any Depositary Receipts, the Company shall deliver to Investor and to the Stichting (as to the Stichting, to the extent not received by the Stichting as a shareholder of the Company): 

 

	 	(a)	promptly, and no later than one (1) Business Day following the occurrence of any Suspension Event, a notice of such Suspension Event which notice will include the
date and the nature of the Suspension Event, the identity of any Third Party involved in such Suspension Event, and such Third Party’s Ownership at the time of such notice to the extent this information is not public and the Company is allowed
to do so; 

  

	 	(b)	promptly, and no later than one (1) Business Day following the occurrence of any event terminating a Suspension Event, a notice of such termination, which notice
will identify, as applicable, (i) the termination or withdrawal of any Third Party Offer, and (ii) to the extent known by the Company, the Ownership by the Third Party that is or includes a Control Investor of less than twenty per cent
(20%) of the Disclosed Shares Outstanding as of the date of such notification, or by any other Third Party, less than thirty per cent (30%), of the Disclosed Shares Outstanding as of the date of such notification to the extent this information
is not public and the Company is allowed to do so; and 

  

	 	(c)	promptly, and no later than one (1) Business Day following the occurrence thereof, notice of any Termination Event. 

 

	5.2	Financial Information 

For so long as Investor Parent applies the equity method of accounting to Investor Parent’s interest in the Shares under applicable
accounting standards, 

  
 15 / 26

 
the Company will prepare, in accordance with US GAAP, quarterly, semi-annual and annual financial statements having a scope of presentation that is substantially consistent with that of the
quarterly, semi-annual and annual financial statements that the Company has published in the 12 months preceding the date of this Agreement and will make public or, in the absence of such publication by the Company, deliver such applicable
statements to Investor no later than seventy (70) days after the last day of each fiscal quarter of the Company (the “Available Financial Information”). In the event that applicable standards for the equity method of accounting
for SEC reporting by Investor would make it necessary for Investor to use financial information of the Company other than the Available Financial Information, upon Investor Parent’s reasonable request and at Investor Parent’s expense the
Company will prepare such additional financial information in accordance with such applicable standards and requirements and deliver such information, to the extent permitted by applicable Law, to Investor Parent promptly but not later than seventy
(70) days (or such shorter time period as may be required under applicable requirements at such time) after the last day of each fiscal quarter of the Company. 
  

	6	TRANSFERS OF SHARES 

  

	6.1	Limited Transferability 

Except as otherwise provided herein, Investor and its Affiliates shall not Transfer any Stichting Shares or Depositary Receipts;
provided, however, that 
  

	 	(a)	Investor and its Affiliates may engage in Hedging with respect to any Stichting Shares or Depositary Receipts at any time, provided that such Hedging would not in any
event require that any of the Stichting Shares be released from the Stichting or Depositary Receipts be transferred except as otherwise permitted by the other provisions of this Agreement; and 

 

	 	(b)	Investor and its Affiliates Owning Depositary Receipts may transfer, assign or sell any Depositary Receipts to any Affiliate of Investor which is a wholly owned
subsidiary of Investor Parent, which subsidiary will then be subject to the rights and obligations set forth in this Agreement with respect to such Depositary Receipts so transferred and any such transfers, assignments or sales shall not be
Transfers for purposes of this Agreement; provided, that (i) Investor Parent shall guarantee the performance of all of such subsidiary’s obligations under this Agreement, and (ii) any such subsidiary shall transfer such
Depositary Receipts back to Investor or another wholly-owned subsidiary of Investor Parent within five (5) calendar days after ceasing to be a wholly owned subsidiary of Investor Parent. 

  
 16 / 26

	 	(c)	Investor shall transfer all Depositary Receipts Owned by it to a wholly-owned subsidiary of Investor Parent within five (5) calendar days after ceasing to be a
wholly owned subsidiary of Investor Parent. 

  

	6.2	Max 4% Market Sales 

 In
no event shall Investor and its Affiliates, without the prior written consent of the Company, Transfer Shares or direct the Stichting to Transfer Stichting Shares on Euronext Amsterdam, NASDAQ or any other securities exchange on which the Shares are
then being traded (a “Market Sale”) during any six (6) month period that in the aggregate would exceed four per cent (4%) of the Disclosed Shares Outstanding immediately prior to such Market Sale. For the avoidance of
doubt, no Transfer of Shares effected by way of a Block Trade or underwritten offering shall be deemed to constitute a Market Sale. 
  

	6.3	Limited Transfer to Certain Competitors or Customers 

  

	6.3.1	In no event shall Investor or its Affiliates, without the prior written consent of the Company, Transfer Shares or direct the Stichting to Transfer Stichting Shares in
a Block Trade to a Specified Company. 

  

	6.3.2	In no event shall Investor or its Affiliates, without the prior written consent of the Company, Transfer Shares or direct the Stichting to Transfer Stichting Shares in
a Block Trade to a Specified Customer unless the Specified Customer (i) agrees in advance to be bound by a shareholder agreement with the Company substantially similar to this Agreement and (ii) enters into such agreement effective as of
the date of the Transfer. For the avoidance of doubt, in the event a Specified Customer agrees to be bound by such agreement, Investor or any of its Affiliates may Transfer Depositary Receipts to such Specified Customer, but shall not be permitted
to instruct the Stichting to Transfer the Stichting Shares corresponding to such Depositary Receipts to such Specified Customer. 

  

	6.4	Proceeds of Transfer 

 The
proceeds of any Transfer in compliance with this Agreement of Stichting Shares corresponding to the Depositary Receipts shall be paid directly to an account established by and in the name of Investor or its relevant Affiliate. 

 

	7	DURATION AND TERMINATION 

  

	7.1	Term 

 This Agreement is
effective as of the date hereof and shall remain in effect for an indefinite period of time and cannot be terminated during such period, save 

  
 17 / 26

 
as provided in Section 7.2.2. 
  

	7.2	Termination 

  

	7.2.1	Save as provided in Section 7.2.2, this Agreement cannot be terminated as long as Investor or any of its Affiliates Owns any Depositary Receipts.

  

	7.2.2	This Agreement shall terminate, and, if applicable, all Depositary Receipts shall be promptly exchanged for the Shares corresponding to such Depositary Receipts, and
the Stichting dissolved, upon the earliest to occur of the following dates or events: 

  

	 	(a)	the date that is eighteen (18) months after an exchange of Depositary Receipts for Shares in accordance with Section 3.3.3(a) or (b), provided, that
Investor was at no time during such eighteen (18) month period required to re-deposit Shares into the Stichting pursuant to this Agreement; and 

  

	 	(b)	a Termination Event; and 

  

	 	(c)	the winding up or liquidation of the Company, either on a voluntary or non-voluntary basis. 

 

	7.2.3	Upon the termination of this Agreement pursuant to Section 7.2.2, the Parties shall, as promptly as practicable, effect the exchange of any Depositary Receipts
still outstanding for a corresponding number of Shares. 

  

	7.3	Survival 

 Sections 1
(Interpretation) and 8 (Miscellaneous) shall survive in the event of the termination of this Agreement. 
  

	8	MISCELLANEOUS 

  

	8.1	Further assurances; No Inconsistent Agreements 

  

	8.1.1	Each Party shall from time to time execute such documents and perform such acts and things as the other Party may reasonably require to give such other Party the full
benefit of this Agreement. 

  

	8.1.2	 For the duration of the Lock-Up Period, the Company will not, without the prior written consent of Investor, enter into any agreement that provides for
the issuance by the Company of Shares to any of its customers under a customer equity participation plan of a similar nature as contemplated by this Agreement and the NRE Agreements (i) on terms and conditions that are, in the aggregate,
materially more favourable to such other customer than the terms 

  
 18 / 26

	 	
and conditions contained in this Agreement and the NRE Agreements (including in respect of the ratio of the number of Shares to be subscribed by such customer to the NRE contribution by such
customer to fund the Company’s expenditures under its non-recurring engineering program, without restriction on the subscription price per Share to be issued to such customer). 

 

	8.2	Entire agreement 

 This
Agreement (including the agreements identified herein) contains the entire agreement between the Parties relating to the subject matter of this Agreement, to the exclusion of any terms implied by Law which may be excluded by contract, and supersedes
any previous written or oral agreement between the Parties in relation to the matters dealt with in this Agreement. 
  

	8.3	No assignment 

 Except as
otherwise expressly provided in this Agreement, no Party may, unless with the prior written consent of the other Parties, assign, grant any security interest over or otherwise transfer, in whole or in part, any of its rights and obligations under
this Agreement; provided, that Investor may assign any or all of its rights and obligations under this Agreement to an Affiliate which is a wholly-owned subsidiary of Investor Parent to which Investor or an Affiliate Owning Depositary
Receipts transfers any Shares or Depositary Receipts; provided, that (i) Investor Parent shall guarantee the performance of all of such subsidiary’s obligations under this Agreement, and (ii) any such subsidiary shall transfer
such Shares or Depositary Receipts back to Investor or another wholly-owned subsidiary of Investor Parent within five (5) calendar days after ceasing to be a wholly-owned subsidiary of Investor Parent. Subject to the preceding sentence, this
Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns. 
  

	8.4	Waiver 

 No failure or
delay of a Party in exercising any right or remedy hereunder will operate as a waiver thereof, nor will any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any
course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. No waiver of any provision of this Agreement shall be effective unless in writing and signed by or on behalf of the Party entitled to give
such waiver. 
  

	8.5	Amendment 

 No amendment
of this Agreement shall be effective unless in writing and 

  
 19 / 26

 
signed by or on behalf of each of the Parties. 
  

	8.6	Third Party Rights 

 Save
as expressly otherwise stated, this Agreement does not contain a stipulation in favour of a Third Party (derdenbeding). 
  

	8.7	Rescission; Remedies 

Each Party waives its right to rescind (ontbinden) this Agreement on the basis of section 6:265 of the Dutch Civil Code.
Furthermore, a mistaken Party shall bear the risk of any mistake (dwaling) in making this Agreement. In the event of a breach of this Agreement by any of the parties, the other Party may be entitled to claim for damages
(schadevergoeding) and/or specific performance (nakoming). Except as otherwise limited by this Agreement, the rights and remedies of the Parties hereunder are independent, cumulative and in addition, and without prejudice, to any
rights or remedies which they would otherwise have hereunder 
  

	8.8	Costs 

 Unless this
Agreement provides otherwise, all costs which a Party has incurred or must incur in preparing, concluding or performing this Agreement are for that Party’s own account. Notwithstanding the foregoing, in the event that any action, suit or other
proceeding is instituted concerning or arising out of this Agreement or any transaction contemplated hereunder, the prevailing party will recover all of such party’s costs and attorneys’ fees incurred in each such action, suit or other
proceeding, including any and all appeals or petitions therefrom. 
  

	8.9	Language 

 The language of
this Agreement is English, which is to be the official language of this Agreement’s text and interpretation, and all notices, minutes or meetings in connection with this Agreement shall be in writing in English or conducted in English. All
demands, requests, statements, certificates or other documents or communications to be provided in connection with this Agreement must be in English or accompanied by a certified English translation, in which case the English translation prevails
unless the document or communication is a statutory or other official document or communication 
  

	8.10	Notices 

  

	8.10.1	Any notice in connection with this Agreement must be: 

  
 20 / 26

	 	(a)	in writing; and 

  

	 	(b)	delivered by hand, e-mail, fax, registered post, courier, writ or petition as provided in Section 8.10.7. 

 

	8.10.2	Investor nominates the address referred to below as its place of residence at which notices may be served for all matters in connection with this Agreement:

 Intel Holdings B.V. 
 c/o Intel Corporation 2200 Mission College Boulevard 
 Santa Clara, California
95054 
 USA 
 Attention: Intel Capital General Counsel 
 E-mail: marty.m.linne@intel.com

 Fax: +1 (408) 653-9098 
  

	8.10.3	The Stichting nominates the address referred to below as its place of residence at which notices may be served for all matters in connection with this Agreement:

 Claude Debussylaan 24 
 1082 MD Amsterdam 
 Attention: Jeroen van Dijk and Douglas Tessers 

E-mail: j.vandijk@ant-trust.nl / d.tessers@ant-trust.nl 
 Fax: +31 20 - 522 25 00 
  

	8.10.4	The Company nominates the address referred to below as its place of residence at which notices may be served for all matters in connection with this Agreement:

 De Run 6501 
 5504 DR, Veldhoven 
 The Netherlands 

Attention: General Counsel 
 E-mail: robert.roelofs@asml.com 
 Fax: +31 40 268 4888 

 

	8.10.5	A copy of each notice shall be simultaneously sent (which shall not constitute notice): 

 

	 	(a)	for Investor to: 

 Intel Capital
Corporation 
 c/o Intel Corporation 

  
 21 / 26

 Attn: Intel Capital Portfolio Manager 

2200 Mission College Blvd. 
 M/S RN6-59 
 Santa Clara, CA 95054 

Email: portfolio.manager@intel.com 
 And: 
 Gibson, Dunn & Crutcher LLP 

1881 Page Mill Road 
 Palo Alto, California 94304 
 USA 

Attention: Russell C. Hansen 
 Email: RHansen@gibsondunn.com 
 Fax: +1 650-849-5083 

And: 

NautaDutilh N.V. 
 Strawinskylaan 1999 
 1077 XV Amsterdam 

The Netherlands 

Attention: Gaike Dalenoord 
 Email: Gaike.Dalenoord@nautadutilh.com 
 Fax: +31 20-71-71-327 

 

	 	(b)	for the Stichting to: 

NautaDutilh N.V. 
 Strawinskylaan 1999 
 1077 XV Amsterdam 

The Netherlands 

Attention: Gaike Dalenoord 
 Email: Gaike.Dalenoord@nautadutilh.com 
 Fax: +31 20-71-71-327 

 

	 	(c)	for the Company to: 

 De Brauw
Blackstone Westbroek N.V. 
 Attention: Arne Grimme and Martin van Olffen 

E-mail: arne.grimme@debrauw.com OR 
 martin.vanolffen@debrauw.com 
 Fax: +31 20 577 1775 

 

	8.10.6	 A Party may from time to time nominate a different place for notice or contact

  
 22 / 26

	 	
person by notifying the other Parties of that new place for notice or contact person. 

  

	8.10.7	A notice will be deemed duly given or delivered (a) on the date of delivery if delivered personally, (b) on the date of sending if sent by e-mail,
(c) upon electronic confirmation of receipt by facsimile if by facsimile but if not transmitted on a Business Day, the first Business Day following transmission, provided that a copy of such notice or other communication is promptly
mailed by registered or certified mail, return receipt requested, postage prepaid, following the transmission of such facsimile, (d) on the first Business Day following the date of dispatch if delivered utilizing a next-day service by a
nationally recognized next-day courier (or in the case of any recipients sending or receiving notices to Parties internationally, then on the second Business Day following the date of dispatch) or (e) on the earlier of confirmed receipt or the
fifth Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. 

  

	8.11	Invalidity 

  

	8.11.1	If any provision in this Agreement is held to be illegal, invalid or unenforceable, in whole or in part, under any Law: 

 

	 	(a)	such provision or part shall to that extent be deemed not to form part of this Agreement but the legality, validity or enforceability of the remainder of this Agreement
shall not be affected and shall remain in full force and effect so long as the economic or legal substance of the transaction contemplated by this Agreement is not affected in any manner materially adverse to any party; and 

 

	 	(b)	the Parties shall negotiate in good faith and use reasonable efforts to agree a replacement provision that is legal, valid and enforceable to achieve so far as possible
the intended effect of the illegal, invalid or unenforceable provision in a mutually acceptable manner, in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the fullest extent possible.

  

	8.12	Counterparts 

 This
Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. This Agreement may be executed by facsimile or electronic (.pdf) signature and a facsimile or electronic (.pdf)
signature will constitute an original for all purposes. 

  
 23 / 26

	8.13	Dispute resolution 

  

	8.13.1	Subject to Section 8.13.10, all disputes being capable of settlement by arbitration under Dutch law arising out of, in connection with or relating to this
Agreement, including any question(s) regarding its formation, existence, validity, enforceability, performance, interpretation or termination, shall be finally resolved by arbitration under the Rules of Arbitration (the “ICC Rules”)
of the International Chamber of Commerce (“ICC”), subject to the provisions of this Section 8.13. 

  

	8.13.2	Prior to arbitration for all matters other than an Injunctive Matter, however, the Party making the original claim shall provide the other Party with a written
description of its claim against or dispute with the other Party, and one or more of the senior executives of each Party shall meet in an attempt to resolve such dispute or claim. If the disagreements cannot be resolved by the senior management
after thirty (30) days from the date any Party made a written demand for resolution, either Party may submit such dispute(s) to arbitration in accordance with the provisions of this Section 8.13. 

 

	8.13.3	There shall be three (3) arbitrators: The claimant shall nominate one (1) co-arbitrator in the request for arbitration; respondent shall nominate one
co-arbitrator in the answer to the request; and the two co-arbitrators, once appointed, shall have thirty (30) days to nominate the chair, failing which the third arbitrator shall be appointed by the ICC Court of International Arbitration.

  

	8.13.4	The place of arbitration shall be London, England. Any hearings or meetings in connection with such arbitration shall take place in London, England or such other place
as the Parties may agree. 

  

	8.13.5	The language of the arbitration shall be English. Documents and written testimony may be submitted in any language; provided that the Party submitting such documents
and written testimony shall provide, at its own expense, a translation of the relevant portions of documents and the entirety of the written testimony in the English language. 

  
 24 / 26

	8.13.6	In matters relating to evidence and disclosure, the arbitral tribunal shall be guided by the International Bar Association Rules on the Taking of Evidence in
International Arbitration (2010). 

  

	8.13.7	The arbitration award shall be final and binding. The Parties expressly agree that no application under Section 45 of the English Arbitration Act 1996 and no leave
to appeal under Section 69 of the English Arbitration Act of 1996 shall be sought with respect to any question of law arising during the course of the arbitration or with respect to any award made. 

 

	8.13.8	The Parties agree to maintain the confidentiality of the arbitral proceedings, including the existence of the same and the status of the hearings, and shall act in
accordance with the non-disclosure arrangements agreed between the Parties in connection with the Investment Agreement. In addition, the Parties undertake to maintain the confidentiality of any information and documents produced in the arbitration
proceedings by another Party as well as the confidentiality of witness statements, witness testimony, and transcripts, and of any materials created by the arbitral tribunal for the purpose of the arbitration proceedings, including any order(s) and
award(s). Notwithstanding the foregoing, if the disclosure of the arbitral proceedings, or of any of the aforementioned information, testimony, transcripts, documents, and materials, including any order(s) and award(s), is required by applicable Law
or is compelled by a court or other Governmental Entity, the Parties shall act in accordance with Section 4.9 of the Investment Agreement. 

  

	8.13.9	Nothing in this Section 8.13 shall prevent any Party, before an arbitration has commenced under this Section or any time thereafter, from applying for conservatory
and interim relief measures (an “Injunctive Matter”), including, but not limited to, temporary restraining orders or preliminary injunctions, or their equivalent, from any court of competent jurisdiction. The Parties hereby agree to
opt-out of the Emergency Arbitrator Provisions under Article 29 of the ICC Rules; such Emergency Arbitrator Provisions shall not apply to any disputes arising out of, in connection with or relating to this Agreement. 

 

	8.13.10	Each Party hereby irrevocably consents to and agrees to accept and acknowledge service at the address for such process set forth in Section 8.10 of any and all
process against such party in any legal proceeding as contemplated in this Section 8.13. 

  
 25 / 26

	8.13.11	This Section 8.13 shall survive the termination of this Agreement for any reason. 

 

	8.14	Governing law 

 This Agreement and the
documents to be entered into pursuant to it, save as expressly otherwise provided therein, shall be governed by and construed in accordance with the Law of the Netherlands. 

 

	9	INVESTOR PARENT GUARANTEE 

 Investor
Parent irrevocably and unconditionally guarantees to the Company and the Stichting the due performance by Investor of its obligations under this Agreement. 
 [SIGNATURE PAGES FOLLOW] 

  
 26 / 26

 AGREED AND SIGNED BY: 

 

									
	Intel Holdings B.V.	 		 		 	
			
	 /s/ Tiffany Doon Silva
	 		 	 /s/ Shlomo Cohen

	Name:	 	Tiffany Doon Silva	 		 	Name:	 	Shlomo Cohen
	Title:	 	Director A	 		 	Title:	 	Director B
	Date:	 		 		 	Date:	 	

 [Intel Shareholder Agreement Signature Page] 

									
	Intel Corporation	 		 		 	
			
	 /s/ Cary Klafrer
	 		 	 /s/ Douglas M. Lusk

	Name:	 	Cary Klafrer	 		 	Name:	 	Douglas M. Lusk
	Title:	 	Corporate Secretary	 		 	Title:	 	Assistant Treasurer
	Date:	 		 		 	Date:	 	

 [Intel Shareholder Agreement Signature Page] 

									
	Stichting Administratiekantoor MAKTSJAB	 		 	
			
	 /s/ Hieronymus Maria van Dijk
	 		 	 /s/ Douglas Charles Tessers

	Name:	 	Hieronymus Maria van Dijk	 		 	Name:	 	Douglas Charles Tessers
	Title:	 	Director	 		 	Title:	 	Director
	Date:	 		 		 	Date:	 	

 [Intel Shareholder Agreement Signature Page] 

									
	ASML Holding N.V.	 		 	
			
	 /s/ Peter Wennink
	 		 	 /s/ Eric Meurice

	Name:	 	Peter Wennink	 		 	Name:	 	Eric Meurice
	Title:	 	Chief Financial Officer	 		 	Title:	 	Chief Executive Officer
	Date:	 		 		 	Date:	 	

 [Intel Shareholder Agreement Signature Page] 

	Schedule 1	Definitions and Interpretations 

  

	1.	Definitions  

 Any
capitalised term, including those used in the introduction and preamble of this Agreement, has the meaning as defined below: 

“Affiliate” means, with respect to any Person, any corporation, partnership, or other business or legal entity that,
directly or indirectly, controls, is controlled by, or is under common control with such Person. The term “control” means, for purposes of this definition, the possession, direct or indirect, of the power to direct or cause the direction
of the management and policies of an entity, whether through the ownership of voting securities or by contract. Control will be presumed if one entity owns, either of record or beneficially, fifty per cent (50%) or more of the capital stock or
share capital entitled to vote for the election of directors of the entity or fifty per cent (50%) or more of equity or voting interest of the entity. For the avoidance of doubt, for purposes of this Agreement, the officers and directors of
Investor and any Person or Persons of which they are Affiliates (other than Investor and its subsidiaries as to which Investor owns, either of record or beneficially, fifty per cent (50%) or more of the capital stock or share capital entitled
to vote for the election of directors of the entity or fifty per cent (50%) or more of equity or voting interest) shall not be deemed Affiliates of Investor; 
 “AFM” means the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten). 
 “Agreement” means this Shareholder Agreement, including any and all of its Schedules as attached hereto; 
 “Amsterdam Shares” means the registered Ordinary Shares of the Company listed for trading on NYSE Euronext Amsterdam; 

“Available Financial Information” has the meaning set out in Section 5.2; 

“Block Trade” means a transaction in which Investor or any of its Affiliates Transfers Shares to a Third Party or Third
Parties identified to Investor or its Affiliates in a privately negotiated Transfer; 
 “Business Day” means any
day that is not a Saturday, a Sunday or other day on which banks are authorized by Law to be closed in The City of New York or Amsterdam, The Netherlands; 
 “Change of Control Transaction” means any transaction or series of transactions (whether structured as a stock purchase, merger, consolidation, reorganization, change in organizational
form, spin-off, split-off, recapitalization, sale of equity interests or other 

 
similar transaction or otherwise) that results directly or indirectly, in the shareholders of the Company immediately prior to such transaction or transactions ceasing to be entitled to exercise
at least fifty per cent (50%) of the votes in the General Meeting or in the general meeting of shareholders of the entity resulting from such transaction or series of transactions; 

“Company” has the meaning set out in the preamble; 

“Conditions of Administration” means the conditions under which the Stichting holds the Stichting Shares and issues the
Depositary Receipts in the form attached as Schedule 2, as may be amended; 
 “Control Investor” means a Third
Party other than a financial institution, bank, insurance company, mutual fund, pension fund or other institutional investor which acquires equity securities of operating companies in the ordinary course of its business solely as a
“passive” investment without any purpose, nor with the objective, of changing or influencing the control of the operating company, nor in connection with or as a participant in any transaction having such purpose or objective. Without
limiting the foregoing, a Control Investor would include (i) any Person whose principal business operates in the semiconductor manufacturing or design or semiconductor manufacturing equipment industry or (ii) any private equity investment
firm that raises capital for, and acts as an investment manager in connection with, the making of investments in the equity of operating companies with the purpose of changing or influencing the control of such operating companies or (iii) a
Third Party of any kind which states or announces, or discloses in a filing with the SEC (which may include a filing on Schedule 13D) or AFM, any plan or intention, with respect to the Shares acquired or to be acquired by such Third Party, to change
or influence the control of the Company; 
 “Depositary Receipts” means the depositary receipts issued by the
Stichting to Investor or any of its Affiliates corresponding with the Stichting Shares; 
 “Disclosed Shares
Outstanding” means, as to any date of determination, the Company’s total number of Shares outstanding as disclosed by the Company in its most recent Form 20-F or Form 6-K filed with the SEC or as certified by an officer of the Company
in a notice delivered to Investor subsequent to such filing; 
 “Employee Benefit Plan” means any plan,
agreement or arrangement (including without limitation any “employee benefit plan” as defined in Section 3(3) of ERISA) and any trust or other funding medium relating thereto with respect to which Investor has or may have any
liability or whereby Investor and any of its Affiliates provides or is obligated to provide any benefit, to any current or former officer, director, employee or other individual, including, without limitation, any profit sharing, “golden
parachute,” deferred compensation, incentive compensation, stock option, stock purchase, Code Section 125 

 
cafeteria plan or flexible benefit arrangement, rabbi trust, severance, retention, supplemental income, change in control, fringe benefit, perquisite, pension, retirement, health or insurance
plans, agreements, or arrangements. 
 “Euronext Amsterdam” means the stock exchange of Euronext Amsterdam by
NYSE Euronext, the regulated market of Euronext Amsterdam N.V. or, in the event the Ordinary Shares of the Company are no longer traded on such exchange, the principal exchange on which such Ordinary Shares are then traded; 

“General Meeting” means the Company’s general meeting of shareholders; 

“Governmental Entity” means any federal, national, supranational, state, provincial, local or similar government,
governmental, regulatory, administrative or quasi-governmental authority, branch, office agency, commission or other body, or any court, tribunal, or arbitral or judicial body (including any grand jury) in any jurisdiction; 

“Hedging” means any swap, derivative transaction or similar arrangement entered into by Investor or its Affiliates and
any other Person to manage investment risk in relation to any Shares or Depositary Receipts; 
 “Hostile Offer”
has the meaning set out in Section 4.3.1; 
 “ICC” has the meaning set out in Section 8.13.1;

 “ICC Rules” has the meaning set out in Section 8.13.1; 

“Injunctive Matter” has the meaning set out in Section 8.13.9; 

“Investment Agreement” has the meaning set out in Recital (B); 

“Investor” means Intel Holdings B.V., a private limited liability company, incorporated in the Netherlands; 

“Investor Parent” means Intel Corporation, a Delaware corporation; 

“Law” means any applicable statute, law, ordinance, regulation, directive, rule, code, executive or other order,
injunction, judgment, decree, writ, order or other requirement, including any successor provisions thereof, of any Governmental Entity; 
 “Lock-Up Period” means the period referred to in Section 4.1.1; 
 “Management Board” means the management board of the Company; 

“Market Sale” has the meaning set out in Section 6.2; 

 “Maximum Shareholding” means nineteen-and-nine-tenths per cent
(19.9%) of the Disclosed Shares Outstanding, or such higher percentage as provided for in Section 3.2; 
 “New
York Shares” means the registered Shares of the Company, each representing one Ordinary Share, listed for trading on the NASDAQ Stock Market; 
 “Non-Controlled Employee Benefit Plan” shall mean an Employee Benefit Plan for which neither Investor nor any of its Affiliates exercises discretionary authority or control with
respect to management of assets of the Employee Benefit Plan or the disposition of assets held in such Employee Benefit Plan or in relation to which Investor is acting in partnership or concert with in relation to the Shares; 

“NRE Agreements” mean the agreements, dated 9 July 2012, entered into by Investor Parent and the Company setting
forth the terms of Investor Parent’s contribution to the funding of new technologies; 
 “Ordinary Shares”
means the ordinary shares of the Company. For purposes of this Agreement, references to Ordinary Shares include both New York Shares and Amsterdam Shares; 
 “Other Investor” has the meaning set out in the Investment Agreement; 
 “Outside Shares” has the meaning set out in Section 3.5; 

“Own” or “Ownership” means legal or beneficial ownership (including but not limited to shares held for
the account of the beneficial owner), directly or indirectly, of any Shares; 
 “Parties” means Investor, the
Stichting and the Company, and “Party” means any one of them or the relevant one of them, as the context requires; 
 “Person” means individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other legal entity including any Governmental Entity.

 “Schedule” means any Schedule as attached to and forming a part of this Agreement; 

“SEC” means the United States Securities and Exchange Commission; 

“Shares” means the Ordinary Shares in the authorised share capital of the Company, any Class M Shares in the authorised
share capital of the Company and/or any other shares of any category issued, except any category of shares issued to Stichting Preferente Aandelen ASML or issuable upon exercise of an option by Stichting Preferente Aandelen ASML; 

“Specified Company” means a company that receives substantial revenues from the sale of products and services that
compete with the principal products and services of the 

 
Company and whose name is set out on Schedule 3, as the same may be amended by the Company upon notice to Investor pursuant to Section 8.10 no more than once per year to reflect the
Company’s good faith determination that a change has taken place in the identity of its principal competitors; provided, however, that such Schedule shall include no more than five (5) companies at any one time; 

“Specified Customer” means a company that is a customer of the Company accounting for at least ten per cent (10%) of
the revenues of the Company in the last twelve (12) months and whose name is set out on Schedule 4, as the same may be amended by the Company upon notice to Investor pursuant to Section 12.10 no more than once per year to substitute any
other customer that accounted for at least ten per cent (10%) of the Company’s revenues in the last twelve (12) months; provided, however, that such Schedule shall include no more than five (5) companies at any one
time; 
 “Standstill Period” has the meaning set out in Section 3.1.1; 

“Stichting” has the meaning set out in the preamble; 

“Stichting Articles” means the articles of association of the Stichting, as attached hereto in draft in Schedule 2 (as
the same may be amended from time to time); 
 “Stichting Shares” means the Shares of the Company held by the
Stichting by way of administration (ten titel van beheer); 
 “Supervisory Board” means the supervisory
board of the Company; 
 “Suspension Event” means (a) a Third Party Acquisition, (b) a Third Party
Offer or (c) the Company’s announced intention to enter into a Change of Control Transaction; provided, that for purposes of this definition, a “Suspension Event” is deemed to be continuing (i) with respect to
clause (a), so long as such Third Party possesses Ownership representing at least thirty per cent (30%), or, in the case of a Control Investor, twenty per cent (20%), of the Disclosed Shares Outstanding; (ii) with respect to clause (b), so long
as such Third Party’s offer has not been withdrawn, terminated or completed and (iii) with respect to clause (c), so long as such announced Change of Control Transaction has not been terminated or completed; 

“Termination Event” means (i) the completion of the acquisition or series of acquisitions of Shares by a Third Party
as a direct or indirect result of which, the shareholders of the Company immediately prior to such transaction or transactions cease to hold at least fifty per cent (50%) of the Company’s outstanding Shares; (ii) the Company’s
completion of a Change of Control Transaction; or (iii) the involuntary delisting of the Ordinary Shares from Euronext Amsterdam or the NASDAQ Stock Market; or (iv) the voluntary delisting by the Company of the Ordinary Shares from
Euronext Amsterdam or the NASDAQ Stock 

 
Market except where the Company has moved its listing in the United States from the NASDAQ Stock Market to the New York Stock Exchange; 

“Third Party” means a Person other than the Company, Investor or an Affiliate of Investor, and includes any two
(2) or more of such Persons acting together as a group for the purpose of acquiring, holding or disposing of securities of the Company, and all Shares subject to any offer by, or acquired or Owned by such Third Parties and Affiliates of such
Third Parties will be aggregated together for the purposes of this Agreement; 
 “Third Party Acquisition” means
the completion of any transaction or series of transactions as a direct or indirect result of which (i) a Control Investor Owns at least twenty per cent (20%) of the Disclosed Shares Outstanding or (ii) any Third Party Owns at least
thirty per cent (30%) of the Disclosed Shares Outstanding, provided, that a Third Party Acquisition will not include a Change of Control Transaction; 
 “Third Party Offer” means a bona fide public offer by (i) any Control Investor to acquire, directly or indirectly, Ownership of at least twenty per cent (20%) of the Disclosed
Shares Outstanding or (ii) any Third Party to acquire, directly or indirectly, Ownership of at least thirty per cent (30%) of the Disclosed Shares Outstanding; 
 “Transfer” has the meaning set out in Section 4.1.1; 

“U.S. GAAP” means United States generally accepted accounting principles as in effect from time to time; 

“Voting Notice” has the meaning set out in Section 2.4.3. 

 

	2.	Headings and references to Sections, Schedules and Paragraphs 

  

	 	(a)	Headings have been inserted for convenience of reference only and do not affect the interpretation of any of the provisions of this Agreement. 

 

	 	(b)	A reference in this Agreement to: 

  

	 	(i)	a Section or Schedule is to the relevant Section of or Schedule to this Agreement; and 

 

	 	(ii)	a Paragraph is to the relevant Paragraph of the relevant Schedule. 

  

	3.	Information 

 References
to books, records or other information include books, records or other information stored in any form, including paper, magnetic media, films, microfilms, electronic storage devices and any other data carriers. 

	4.	Other references 

  

	 	(a)	Whenever used in this Agreement, the words ‘include’, ‘includes’ and ‘including’ are deemed to be followed by the phrase ‘without
limitation’, ‘but not limited to’, or other equivalents. 

  

	 	(b)	Whenever used in this Agreement, the words ‘as of’ include the day or moment in time specified thereafter. 

 

	 	(c)	Any reference in this Agreement to any gender includes all genders, and words importing the singular include the plural and vice versa.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]